Objectives: To give an overview on prabotulinumtoxin (praBoNTA)

Introduction: PrabotulinumtoxinA (praBoNTA, JeuveauTM, NeuceivaTM, Evolus, Inc. Newport Beach, CA) is one of the new toxins on the market approved for the treatment of glabellar lines in Canada (2018), the US (2019) as well as in Europe (2019). In contrast to other toxins, it will be licensed only for aesthetic indications.

Materials / method: Literature search.

Results: Several RCTs have been conducted to look into the efficacy and safety. One major RCT (EVB 003) included onaBonNTA as comparator. Results from this Phase III clinical trial (n=540) confirmed that a single dose of 20 U praBoNTA was both well-tolerated and non-inferior to 20 U onaBoNTA for the treatment of moderate to severe glabellar lines. Responder rates for the primary efficacy endpoint at day 30 were 87,2 %, 82,8 % and 4,2% for praBoNTA, onaBoNTA and placebo. Further phase II safety studies have been conducted showing an excellent safety profile after long term repeated injections.

Conclusion: PraBoNTA is new efficacious and safe botulinumtoxin preparation. It is approved for the treatment of glabellar lines. In Europe it will be available from fall 2022 on.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Evolus who sponsored the RCT where I participated as an investigqtoe

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): HUGEL

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): HUGEL

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): HUGEL

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: HUGEL

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability